Literature DB >> 22192666

Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry.

Silvia G Priori1, Maurizio Gasparini, Carlo Napolitano, Paolo Della Bella, Andrea Ghidini Ottonelli, Biagio Sassone, Umberto Giordano, Carlo Pappone, Giosuè Mascioli, Guido Rossetti, Roberto De Nardis, Mario Colombo.   

Abstract

OBJECTIVES: The PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) prospective registry was designed to assess the predictive accuracy of sustained ventricular tachycardia/ventricular fibrillation (VTs/VF) inducibility and to identify additional predictors of arrhythmic events in Brugada syndrome patients without history of VT/VF.
BACKGROUND: Brugada syndrome is a genetic disease associated with increased risk of sudden cardiac death. Even though its value has been questioned, inducibility of VTs/VF is widely used to select candidates to receive a prophylactic implantable defibrillator, and its accuracy has never been addressed in prospective studies with homogeneous enrolling criteria.
METHODS: Patients with a spontaneous or drug-induced type I electrocardiogram (ECG) and without history of cardiac arrest were enrolled. The registry included 308 consecutive individuals (247 men, 80%; median age 44 years, range 18 to 72 years). Programmed electrical stimulation was performed at enrollment, and patients were followed-up every 6 months.
RESULTS: During a median follow-up of 34 months, 14 arrhythmic events (4.5%) occurred (13 appropriate shocks of the implantable defibrillator, and 1 cardiac arrest). Programmed electrical stimulation performed with a uniform and pre-specified protocol induced ventricular tachyarrhythmias in 40% of patients: arrhythmia inducibility was not a predictor of events at follow-up (9 of 14 events occurred in noninducible patients). History of syncope and spontaneous type I ECG (hazard ratio [HR]: 4.20), ventricular refractory period <200 ms (HR: 3.91), and QRS fragmentation (HR: 4.94) were significant predictors of arrhythmias.
CONCLUSIONS: Our data show that VT/VF inducibility is unable to identify high-risk patients, whereas the presence of a spontaneous type I ECG, history of syncope, ventricular effective refractory period <200 ms, and QRS fragmentation seem useful to identify candidates for prophylactic implantable cardioverter defibrillator.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22192666     DOI: 10.1016/j.jacc.2011.08.064

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  121 in total

Review 1.  Inherited calcium channelopathies in the pathophysiology of arrhythmias.

Authors:  Luigi Venetucci; Marco Denegri; Carlo Napolitano; Silvia G Priori
Journal:  Nat Rev Cardiol       Date:  2012-06-26       Impact factor: 32.419

2.  Outcome of Insertable Cardiac Monitors in Symptomatic Patients with Brugada Syndrome at Low Risk of Sudden Cardiac Death.

Authors:  Rafi Sakhi; Amira Assaf; Dominic A M J Theuns; Judith M A Verhagen; Tamas Szili-Torok; Jolien W Roos-Hesselink; Sing-Chien Yap
Journal:  Cardiology       Date:  2020-04-22       Impact factor: 1.869

3.  Single oral flecainide dose to unmask type 1 Brugada syndrome electrocardiographic pattern.

Authors:  Sergio Dubner; Damián Azocar; Sebastián Gallino; Alfonso Rafael Cerantonio; Sergio Muryan; Juan Medrano; Carlos Bruno
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-05       Impact factor: 1.468

4.  [Brugada syndrome].

Authors:  Christian Wolpert; Claudia Herrera-Siklody; Ulli Parade; Christian Strotmann; Norman Rüb
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-12

5.  Genotype-phenotype relationship and risk stratification in loss-of-function SCN5A mutation carriers.

Authors:  Tomas Robyns; Dieter Nuyens; Bert Vandenberk; Cuno Kuiperi; Anniek Corveleyn; Jeroen Breckpot; Christophe Garweg; Joris Ector; Rik Willems
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-04-30       Impact factor: 1.468

Review 6.  The Diagnosis, Risk Stratification, and Treatment of Brugada Syndrome.

Authors:  Johannes Steinfurt; Jürgen Biermann; Christoph Bode; Katja E Odening
Journal:  Dtsch Arztebl Int       Date:  2015-06-05       Impact factor: 5.594

Review 7.  [Primary and secondary prophylactic ICD therapy in congenital electrical and structural cardiomyopathies].

Authors:  D Duncker; T König; S Hohmann; C Veltmann
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-05-22

8.  For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death.

Authors:  Ivaylo Tonchev; David Luria; David Orenstein; Chaim Lotan; Yitschak Biton
Journal:  Curr Cardiol Rep       Date:  2019-08-02       Impact factor: 2.931

Review 9.  Pathogenesis and management of Brugada syndrome.

Authors:  Juan Sieira; Gregory Dendramis; Pedro Brugada
Journal:  Nat Rev Cardiol       Date:  2016-09-15       Impact factor: 32.419

10.  Fragmented surface ECG was a poor predictor of appropriate therapies in patients with Chagas' cardiomyopathy and ICD implantation (Fragmented ECG in CHAgas' Cardiomyopathy Study).

Authors:  Adrian Baranchuk; Francisco Femenia; Juan Cruz López-Diez; Claudio Muratore; Mariana Valentino; Enrique Retyk; Nestor Galizio; Darío Di Toro; Karina Alonso; Wilma M Hopman; Rodrigo Miranda
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-09-09       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.